Epithalon：テロメラーゼ活性化ペプチドと長寿研究

Introduction to Epithalon and Bioregulator Peptide Theory

Epithalon (also spelled Epitalon or Epithalone) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (alanyl-glutamyl-aspartyl-glycine). It is based on a naturally occurring peptide extract called Epithalamin, which was isolated from the pineal gland of calves. The research on Epithalon is principally associated with the work of Professor Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, where it has been studied for over three decades as part of a broader program investigating short peptide "bioregulators" and their potential roles in aging and longevity.

The bioregulator peptide theory, as developed by Khavinson and collaborators, proposes that short peptides (typically 2-4 amino acids) can interact with specific DNA sequences and regulate gene expression in a tissue-specific manner. According to this theory, each tissue in the body has characteristic short peptides that help maintain its functional state, and the decline of these endogenous peptides with age contributes to the progressive deterioration of tissue function that characterizes aging. By supplementing with synthetic versions of these peptides, the theory suggests, it may be possible to restore tissue function and slow aspects of the aging process.

Epithalon, as a synthetic version of the pineal gland peptide Epithalamin, occupies a central place in this bioregulator framework. Its primary research interest lies in its reported ability to activate telomerase, the enzyme responsible for maintaining telomere length, and its connection to pineal gland function and melatonin production. This article explores the current research landscape surrounding Epithalon and related longevity peptides. All information is presented for educational purposes only and does not constitute medical advice.

Telomeres, Telomerase, and Aging

To understand the proposed mechanism of Epithalon, it is necessary to review the biology of telomeres and telomerase. Telomeres are repetitive nucleotide sequences (TTAGGG in humans) that cap the ends of chromosomes, protecting them from degradation, fusion, and recognition as damaged DNA. With each cell division, telomeres shorten slightly due to the "end-replication problem" — the inability of conventional DNA polymerases to fully replicate the ends of linear chromosomes.

This progressive telomere shortening acts as a molecular clock that limits the replicative capacity of most somatic cells. When telomeres reach a critically short length, cells enter a state of replicative senescence — they stop dividing and undergo characteristic changes in gene expression and function. Senescent cells accumulate in tissues over time and contribute to age-related tissue dysfunction through the secretion of pro-inflammatory factors, a phenomenon known as the senescence-associated secretory phenotype (SASP).

Telomerase is a ribonucleoprotein enzyme consisting of a catalytic protein subunit (TERT, telomerase reverse transcriptase) and an RNA template component (TERC). When active, telomerase adds TTAGGG repeats to the ends of chromosomes, counteracting the shortening that occurs during DNA replication. Telomerase is highly active in stem cells, germ cells, and certain immune cells, but is expressed at low levels or is absent in most differentiated somatic cells. This differential expression pattern means that stem cells and reproductive cells maintain their telomere length while most body cells progressively lose telomeric DNA over a lifetime.

The connection between telomere biology and aging has been established through multiple lines of evidence, including the observation that individuals with shorter telomeres for their age have increased risk for various age-related diseases, and that rare genetic conditions affecting telomere maintenance (telomeropathies) result in premature aging phenotypes. However, the relationship is complex — telomere length is just one factor among many that contribute to aging, and the therapeutic manipulation of telomerase raises concerns about cancer risk, since telomerase reactivation is a hallmark of most cancers.

Epithalon and Telomerase Activation

The primary claim in Epithalon research is that the peptide can activate telomerase in somatic cells, thereby promoting telomere elongation and potentially extending cellular replicative capacity. This claim is based on several published studies from Khavinson's laboratory and collaborating groups.

In one widely cited study, researchers examined the effects of Epithalon on human fetal fibroblast cultures. They reported that treatment with Epithalon induced telomerase activity in cells that did not normally express significant levels of the enzyme, and that this activation was associated with elongation of telomeres and an extension of the cells' replicative lifespan. Specifically, Epithalon-treated cells were reported to undergo additional cell divisions beyond the normal Hayflick limit (the typical maximum number of divisions for cultured human fibroblasts) without showing signs of malignant transformation.

Additional in vitro studies have reported similar findings in other cell types, including human pulmonary fibroblasts and retinal pigment epithelial cells. In these studies, Epithalon treatment was associated with increased expression of the TERT catalytic subunit of telomerase, suggesting that the peptide may act at the transcriptional level to upregulate telomerase gene expression.

The proposed mechanism by which a tetrapeptide of just four amino acids could influence gene transcription is unusual and remains a subject of discussion in the broader scientific community. Khavinson's group has proposed that short peptides can interact directly with specific DNA sequences through complementary electrostatic and hydrogen bonding interactions, essentially acting as epigenetic regulators that modulate chromatin structure and gene accessibility. While this mechanism has been supported by molecular modeling studies and some experimental evidence from the group, it represents a non-conventional model of gene regulation that has not yet been widely validated by independent laboratories.

The Pineal Gland and Melatonin Connection

Epithalon's origins in pineal gland research connect it to the broader biology of melatonin and circadian rhythm regulation. The pineal gland is a small endocrine organ located in the brain that is best known for producing melatonin, the hormone that regulates sleep-wake cycles. Melatonin production follows a pronounced circadian rhythm, with levels rising in the evening and peaking during the night hours.

Melatonin has been extensively studied for its roles beyond sleep regulation, including potent antioxidant activity, immune system modulation, and potential anti-aging effects. The pineal gland undergoes progressive calcification and functional decline with age, and this decline is associated with reduced melatonin production — a factor that has been proposed to contribute to the sleep disturbances, immune dysfunction, and increased oxidative stress observed in aging populations.

Research by Khavinson's group reported that Epithalon treatment in animal models was associated with restoration of melatonin production toward more youthful levels. In aged rodent studies, Epithalon administration was reported to increase nocturnal melatonin levels and restore a more normal circadian pattern of melatonin secretion. If confirmed, this effect could have implications for sleep quality, antioxidant defense, and immune function in aging organisms.

The connection between Epithalon's telomerase-activating and melatonin-restoring properties is an intriguing aspect of the research. Some investigators have suggested that these effects may be interrelated — that restoration of pineal function could contribute to systemic anti-aging effects through melatonin's broad biological activities, while telomerase activation in pineal cells could help maintain the functional capacity of the gland itself. However, the precise relationship between these two proposed mechanisms remains to be fully elucidated.

Khavinson's Animal Longevity Studies

The most dramatic claims in Epithalon research come from animal longevity studies conducted by Khavinson and colleagues. In a series of experiments spanning multiple animal models and decades of research, the group reported that both Epithalamin (the natural pineal extract) and Epithalon (the synthetic tetrapeptide) could extend lifespan in laboratory animals.

In studies using rodent models, the researchers reported that chronic administration of Epithalon or Epithalamin was associated with lifespan extensions of up to approximately 25% compared to untreated controls. These longevity studies typically involved periodic courses of peptide administration (rather than continuous treatment) and monitored animals from middle age through natural death. In addition to increased mean lifespan, the studies reported reductions in the incidence of spontaneous tumors and improvements in various biomarkers of aging.

Studies in Drosophila (fruit flies) also reported lifespan extension with Epithalon treatment, providing cross-species evidence for the peptide's potential longevity effects. The consistency of results across multiple species was cited as evidence for a fundamental biological mechanism rather than a species-specific effect.

While these results are compelling on their face, several important caveats must be noted. First, the majority of longevity studies on Epithalon have been conducted by a relatively small number of research groups, primarily centered on Khavinson's laboratory. Independent replication by unaffiliated research groups has been limited. Second, the specific experimental protocols, animal strains, housing conditions, and statistical methods used in some of these studies have not always been reported with the level of detail expected by current standards for longevity research. Third, lifespan extension in laboratory animals — particularly in short-lived model organisms — does not necessarily predict longevity effects in humans, whose aging biology is considerably more complex.

FOXO4-DRI: A Senolytic Peptide Approach

While Epithalon approaches aging through telomerase activation, FOXO4-DRI represents a fundamentally different strategy: selectively eliminating senescent cells. FOXO4-DRI is a D-amino acid retro-inverso peptide designed to disrupt the interaction between FOXO4 (Forkhead box O4) and p53, two transcription factors that play critical roles in maintaining senescent cells in a viable but non-dividing state.

In senescent cells, FOXO4 binds to p53 and sequesters it in the nucleus, preventing p53 from triggering apoptosis (programmed cell death). This FOXO4-p53 interaction essentially provides senescent cells with a survival signal that allows them to persist in tissues. By introducing a peptide that specifically disrupts this interaction, FOXO4-DRI releases p53 from FOXO4 sequestration, allowing p53 to activate apoptotic pathways selectively in senescent cells.

Mechanism: p53-FOXO4 Interaction Disruption

The design of FOXO4-DRI exploits a specific protein-protein interaction that is preferentially active in senescent cells. In non-senescent cells, the FOXO4-p53 interaction is not a major survival mechanism, so disrupting it does not significantly affect cell viability. However, in senescent cells that depend on FOXO4-mediated p53 sequestration for survival, FOXO4-DRI effectively removes a critical anti-apoptotic signal.

The "DRI" designation refers to the D-amino acid retro-inverso design of the peptide. In this approach, the peptide sequence is reversed and composed of D-amino acids (mirror images of the natural L-amino acids). This strategy produces a peptide that mimics the spatial arrangement of side chains in the original L-peptide but is resistant to proteolytic degradation by the body's enzymes, which have evolved to recognize and cleave L-amino acid peptide bonds. The result is a peptide with significantly improved metabolic stability and bioavailability.

Research Findings

Published research on FOXO4-DRI, primarily from the laboratory of Peter de Keizer at Erasmus University Medical Center in the Netherlands, demonstrated that the peptide could selectively induce apoptosis in senescent cells in vitro while sparing non-senescent cells. In animal studies using naturally aged and genetically modified fast-aging mice, systemic administration of FOXO4-DRI was associated with reductions in senescent cell markers, improved renal function, restored fitness, and reversal of some phenotypic aspects of aging, including fur regrowth.

These findings generated significant interest in the aging research community as they provided direct evidence that targeted elimination of senescent cells could produce measurable rejuvenation effects. However, FOXO4-DRI research is still in relatively early stages, and the translation of these findings to human applications faces numerous challenges, including optimizing dosing, delivery, and assessing long-term safety of periodic senescent cell clearance.

Cartalax: A Bioregulator for Cartilage and Aging

Cartalax is another peptide from Khavinson's bioregulator program, with the amino acid sequence Ala-Glu-Asp (alanyl-glutamyl-aspartyl). As a tripeptide, it is even shorter than Epithalon and is proposed to function as a tissue-specific bioregulator for cartilage and connective tissue. Cartalax shares two of its three amino acids with Epithalon (which has the sequence Ala-Glu-Asp-Gly), differing only in the absence of the C-terminal glycine.

According to Khavinson's bioregulator framework, Cartalax is proposed to interact with DNA sequences in cartilage cells, modulating gene expression to support chondrocyte function and cartilage matrix maintenance. Published research from the Saint Petersburg Institute has reported that Cartalax treatment was associated with improved cartilage structure and reduced degenerative changes in animal models of aging.

Cartalax has also been studied in the context of broader anti-aging effects. Some publications from Khavinson's group have reported that Cartalax administration was associated with improvements in longevity biomarkers and overall health parameters in aged animals, though the specificity of these effects for cartilage versus systemic effects remains unclear.

As with other bioregulator peptides from this research program, the mechanism by which such a short peptide could produce tissue-specific gene regulatory effects is not widely accepted by the broader scientific community, and independent replication studies are limited. The bioregulator concept remains an active area of research but should be understood as a theoretical framework that requires further validation.

Connection to MOTS-c: Mitochondrial Longevity Peptides

While Epithalon and the Khavinson bioregulators approach longevity through nuclear gene expression and telomere biology, MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) represents a different angle on the aging question — one centered on mitochondrial function and metabolic regulation.

MOTS-c is a 16-amino acid peptide encoded within the mitochondrial genome, specifically within the 12S rRNA gene. It was discovered in 2015 by Dr. Changhan David Lee and colleagues at the University of Southern California. MOTS-c is notable for being one of the few known peptides encoded by mitochondrial DNA (as opposed to nuclear DNA), making it a "mitochondrial-derived peptide" (MDP).

Research has shown that MOTS-c plays a role in regulating cellular metabolism, particularly through its effects on the AMPK (AMP-activated protein kinase) pathway and the folate-methionine cycle. MOTS-c has been reported to enhance glucose metabolism, improve insulin sensitivity, and promote fatty acid oxidation. In animal studies, administration of MOTS-c was associated with prevention of age-related and diet-induced insulin resistance, reduction in obesity, and improved physical performance.

The longevity connection for MOTS-c comes from several observations. First, endogenous MOTS-c levels decline with age, paralleling the age-related decline observed for GHK-Cu and melatonin. Second, administration of MOTS-c to aged mice was reported to improve physical capacity and metabolic function. Third, certain genetic variants of the MOTS-c gene have been associated with exceptional longevity in human population studies, suggesting that mitochondrial-derived peptide signaling may influence human lifespan.

The inclusion of MOTS-c in a discussion of longevity peptides highlights the diversity of approaches being explored in aging research. While Epithalon targets telomere maintenance, FOXO4-DRI targets senescent cell elimination, and MOTS-c targets metabolic function, all three address different aspects of the complex, multifactorial process of aging. This diversity reflects the current scientific understanding that aging is not driven by a single mechanism but by the interplay of multiple deteriorative processes.

Current Evidence Limitations

It is essential to provide a candid assessment of the limitations of the current evidence for longevity peptides, particularly Epithalon. Several important considerations should inform how this research is interpreted:

• Limited independent replication: The majority of published research on Epithalon comes from a relatively small network of research groups associated with or collaborating with Khavinson's laboratory. Independent replication of the key findings — telomerase activation, lifespan extension, and melatonin restoration — by unaffiliated laboratories would significantly strengthen the evidence base.
• Publication in regional journals: Much of the Epithalon research has been published in Russian-language journals or in English-language journals with relatively limited international readership. While this does not invalidate the findings, it does mean that the work has received less scrutiny through the peer review process at high-impact international journals.
• Mechanistic plausibility questions: The proposed mechanism by which a four-amino-acid peptide can interact with DNA and regulate gene expression in a tissue-specific manner is unconventional and has not been widely validated by structural biology or molecular biology studies outside of Khavinson's group. More detailed mechanistic studies using modern techniques such as cryo-electron microscopy, chromatin immunoprecipitation sequencing, and genome-wide association studies would help clarify the mechanism.
• Animal-to-human translation: Even accepting the animal longevity data at face value, the translation to human aging is uncertain. Humans have much longer lifespans, different telomere biology (including shorter telomeres but stricter telomerase regulation compared to many rodent species), and more complex neuroendocrine systems than the laboratory animals used in these studies.
• Absence of human clinical trials: To date, there are no published results from large, well-designed, placebo-controlled clinical trials of Epithalon in humans. Without such trials, the safety and efficacy of Epithalon in humans remain speculative.

The Bioregulator Peptide Theory: Current Status

Khavinson's bioregulator peptide theory represents one of the more ambitious frameworks in peptide research. The theory proposes that the body's tissues rely on a system of short peptide signals for maintaining gene expression patterns and cellular function, and that the age-related decline of these endogenous peptides contributes to the aging process. The therapeutic implication is that supplementation with synthetic versions of these peptides could slow or partially reverse aging at the cellular level.

Khavinson has published extensively on this topic and has described bioregulator peptides for multiple tissues, including the brain (Cortexin, Pinealon), thymus (Thymalin, Thymogen), blood vessels (Vesugen), cartilage (Cartalax), and the pineal gland (Epithalon). Each of these peptides is proposed to have tissue-specific gene regulatory effects based on direct peptide-DNA interactions.

The theory has been met with both interest and skepticism in the broader research community. On one hand, the concept that short peptides could serve as endogenous regulators of gene expression is not inherently implausible — short peptides are known to have diverse biological activities, and the idea that they could interact with DNA or chromatin is supported by some computational and experimental evidence. On the other hand, the specificity and magnitude of the effects claimed for these very short peptides are unusual, and the proposed mechanism of direct peptide-DNA interaction does not align with the conventional understanding of transcriptional regulation.

The ultimate resolution of these questions will require continued research, ideally including independent replication studies, detailed structural biology investigations, and well-designed clinical trials. In the meantime, the bioregulator peptide theory remains an intriguing but incompletely validated hypothesis in the field of aging research.

Summary

The peptides discussed in this article represent several distinct approaches to the challenge of aging and longevity. Epithalon targets telomere maintenance through telomerase activation and may support pineal gland function and melatonin production. FOXO4-DRI addresses the accumulation of senescent cells through targeted disruption of survival signaling. Cartalax exemplifies the bioregulator approach to tissue-specific gene regulation. And MOTS-c highlights the role of mitochondrial-derived peptides in metabolic health and aging.

Each of these approaches has generated published research supporting its potential, but the evidence base varies considerably in quality, quantity, and degree of independent validation. Epithalon has the longest research history but also faces the most significant questions regarding independent replication and mechanistic validation. FOXO4-DRI has strong mechanistic support but limited in vivo data. MOTS-c benefits from its origin in a well-characterized mitochondrial signaling pathway but is still in relatively early stages of investigation.

The field of longevity peptide research continues to evolve, and future studies may clarify the potential and limitations of these compounds. Until more definitive evidence is available, these peptides should be understood as research tools and subjects of scientific investigation rather than proven interventions for extending human lifespan.